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Article: Validation of new symptom-based fibromyalgia criteria for irritable bowel syndrome co-morbidity studies
Sperber AD, Akiva S, Leshno M, Halpern Z, Buskila D
(J Neurogastroenterol Motil 2011;17:67-72)
Patients with irritable bowel syndrome (IBS) frequently pre-
sent non-gastrointestinal (GI) somatic disorders about twice as 
much as a control population.
1 Fibromyalgia (FM), chronic fa-
tigue syndrome, temporomandibular joint disorder and chronic 
pelvic pain are the best documented non-GI somatic comorbi-
dities.
1 The presence of comorbidities in patients with IBS can 
lead to decrease quality of life, increase health care seeking and 
increase medical cost.
2
FM, the most frequently investigated comorbidity of IBS, is 
a soft tissue disorder characterized by diffuse musculoskeletal 
pain and specific tender points on examination.
3 Its prevalence is 
estimated around 2% in the general population and up to 20% 
among rheumatology outpatients.
1,4 However, the prevalence of 
FM in patients with IBS is approximately 32.5% (26%-65%) 
and the prevalence of IBS in patients with FM is approximately 
48% (32%-77%).
1-3 
The high prevalence of non-GI comobidites in IBS suggests 
that there might be common pathophysiologic mechanisms in IBS 
and comorbidities such as abnormal pain sensitivity and descend-
ing pain inhibition, autonomic nervous system dysregulation, 
brain-gut axis dysfunction, immune dysfunction and abnormal-
ities in the levels of serotonin or its receptor.
1,2,5 In addition, psy-
chosocial factors including psychological stress, emotional stress 
and emotional, physical or sexual abuse are trigger factors in both 
IBS and FM.
5 However, these possible common underlying 
pathophysiologic mechanisms have not been proven yet.
2
Although IBS and FM are widely overlapped, gastroentero-
logists usually do not pay attention to FM or other non-GI co-
morbidities when they diagnose or manage patients with IBS. 
And the researchers of IBS clinical trials also have not considered 
this problem when they set the study population or analyze the 
therapeutic effects of certain drugs. In contrast, physicians who 
deal with FM (eg, neurologist, primary care physician, pain spe-
cialist and rheumatologist etc) considered IBS and pain/cramp in 
abdomen as one of 10 most relevant to a diagnosis of FM.
6 
Especially, it is difficult to diagnose or assess FM in the GI clinic Yong Sung Kim
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because it requires a trained rheumatologist to perform physical 
examination according to American College of Rheumatology 
criteria. 
In this issue of the Journal, Sperber et al demonstrated new 
symptom-based FM criteria that can be used in IBS patients 
without physical examination. This study should be welcomed 
because there are several points that gastroenterologists should 
consider about FM in diagnosis and management of IBS. 
First, IBS patients with co-morbid FM might be a new sepa-
rate IBS subgroup. Riedl et al
2 suggest that patients with IBS 
could be categorized according to existence of co-morbidity and 
hypothesized that psychological factors play a common etiological 
role in IBS and co-morbidities. Patients with a high degree of so-
matic co-morbidity also present higher levels of anxiety and de-
pression, as well as a more pronounced decrease in quality of life 
and higher intensity of abdominal pain/discomfort.
7 Because us-
ual conventional management for IBS symptoms could not im-
prove global symptoms in this patients group, it is necessary to 
identify the IBS patient with co-morbid FM and to establish a 
new treatment strategy with optimal consultation. 
Second, FM may contribute the female predominance of 
IBS. Sperber et al recruited only female patients in this study and 
it was based on the fact that the IBS or FM is a predominantly fe-
male disorder. It was one of the major limitations of this study. 
Then, what about the sex difference according to co-morbid FM 
in patients with IBS? Akkuş et al
8 performed a comparative study 
addressing the effects of female predominance of FM on the fe-
male-to-male ratios of IBS. There was a significant female pre-
dominance in patients with IBS + FM (F:M = 5:1), but the 
proportion of male is higher than that of female in patients with 
IBS only (F:M = 2:3). They postulated that coexisting FM in-
creases the female proportion of IBS patients. Although it needs 
to be confirmed in a large study, we should keep FM in mind 
when we see female patients with IBS. 
Third, co-morbid FM could be a confounding factor in clin-
ical trials of therapeutic drug for IBS. Because common patho-
genesis is present in IBS and FM, treatment for IBS could affect 
not only abdominal pain/discomfort but also symptoms of FM 
in IBS patient with co-morbid FM. Low serum level of serotonin 
and tryptophan, low cerebrospinal fluid level of serotonin metab-
olite and increased density of serotonin receptors on circulating 
platelets have been found in patients with FM.
5,9 Therefore we 
can postulate that serotonergic drug used in treatment of IBS 
could have an effect on symptoms of FM, however many clin-
ical trials of serotonergic drugs usually ignored this possibility. 
Although studied with a small number, 5-HT4 agonist, tegaser-
od, improved not only constipation predominant IBS status but 
also FM impact questionnaire score.
9 However, the correlation 
between changes in constipation predominant IBS status and FM 
impact questionnaire score was relatively low and insignificant. 
The 5-HT3 antagonist, ondansetron and tropistron, also improv-
ed pain intensity in studies with patients with FM.
10,11 Another 
interesting finding is the presence of small intestinal bacterial 
overgrowth (SIBO) in patient with FM. Pimentel et al
12 re-
ported that an abnormal breath test was higher in FM (100%) 
than control (20%) or even IBS (84%). Furthermore, signifi-
cantly greater hydrogen production was noted in FM than IBS 
and peak hydrogen level correlated with the degree of somatic 
pain. Although there have been no direct evidence that erad-
ication of SIBO can improve symptoms of FM, in a study with 
IBS patients with co-morbid restless legs syndrome that fre-
quently occurs in FM, restless legs syndrome was significantly 
improved after rifaximin and tegaserod therapy or rifaximin mo-
notherapy.
13 
Interestingly, despite of author’s worry about the propensity 
for reporting pain in IBS patients, IBS patients exhibited rela-
tively low sensitivity of new symptom-based criteria. This un-
expected result might be related to low number of IBS group, 
therefore it needs to be investigated in a large number of IBS 
patients. 
In summary, the very significant study by Sperber et al vali-
dated new symptom-based FM criteria in a population including 
IBS and FM patients for the first time. Although further vali-
dation studies with a large number of patients with IBS in differ-
ent races and cultures are still needed, this study gave us a useful 
tool to approach FM more easily in the GI clinic. In the future, 
gastroenterologists could identify a new IBS subgroup, establish 
a new therapeutic strategy and modify the methodical design in 
clinical trials by using new symptom-based FM criteria.
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